Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216313 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
A Phase 1 study, sponsored by Sagimet Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07216313 is a Phase 1 study that has completed, run by Sagimet Biosciences. The registered enrollment target is 40 participants.
The verdict
NCT07216313, a Phase 1 study, has completed, sponsored by Sagimet Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.
Interventions
- DRUG Resmetirom
- DRUG Denifanstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2025-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216313
The ClinicalTrials.gov registry entry for NCT07216313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sagimet Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Resmetirom is the first listed.
NCT07216313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07216313 about?
NCT07216313 is a clinical study titled "A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants". This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.
What is the current status of trial NCT07216313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-09-30. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT07216313?
The interventions under investigation include: Resmetirom (DRUG), Denifanstat (DRUG).
Who is sponsoring clinical trial NCT07216313?
This trial is sponsored by Sagimet Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.